不同COVID-19疫苗平台作为加强剂次的可互换性:一项模拟真实世界实践的3期研究
这项3期研究于2023年2月14日至6月12日在巴西纳入已全程初免的成人,按既往加强针史分为0、1、2剂组,以2:1:1随机接受SCB-2019、ChAdOx1-S或BNT162b2加强。三种疫苗耐受性相似,针对祖先株和Omicron亚系的免疫原性相当;BNT162b2诱导的抗体滴度最高但第84天抗体衰减最快。
要点
- 全程初免成人中,蛋白、腺病毒载体或mRNA疫苗加强针对祖先株和Omicron亚系均耐受良好且具免疫原性。
- BNT162b2组第28天针对所有变异株的几何平均滴度和几何平均倍数升高高于SCB-2019或ChAdOx1-S组。
- BNT162b2组第84天抗体衰减比SCB-2019或ChAdOx1-S组更迅速。
核心结论
- 在既往接受0-2剂加强针的全程初免成人中,蛋白、腺病毒载体或mRNA疫苗加强针对祖先SARS-CoV-2和Omicron亚系同样耐受良好且具免疫原性。
- BNT162b2诱导的免疫应答最高,但接种3个月后抗体衰减也最快。
研究设计与样本
- 3期研究,2023年2月14日至2023年6月12日纳入既往已免疫成人,按既往加强针史分为0剂(n=26)、1剂(n=140)、2剂(n=606)三个队列。
- 各队列按2:1:1随机接受重组蛋白疫苗(SCB-2019,Clover)、腺病毒载体疫苗(ChAdOx1-S,AstraZeneca/Fiocruz)或mRNA疫苗(BNT162b2,Pfizer/Wyeth)加强。
- 采用ELISA IgG或病毒中和抗体(VNT)检测针对祖先SARS-CoV-2及Omicron BF.7、BQ.1.1.3、XBB.1.5.6亚系的免疫原性,日记卡评估安全性和反应原性。
- 临床试验注册号:ClinicalTrials.gov NCT05812586。
主要发现
- 基线抗体滴度在接受1剂或2剂加强针者中更高。
- 无论既往加强针剂数或所用疫苗如何,所有组针对祖先株和Omicron亚系的滴度均升高。
- 第28天针对所有变异株的几何平均滴度(GMT)和几何平均倍数升高(GMFR)BNT162b2组高于SCB-2019组或ChAdOx1-S组。
- BNT162b2组第84天抗体衰减比SCB-2019组或ChAdOx1-S组更迅速。
- 在各队列内,每种疫苗针对不同SARS-CoV-2株诱导的GMFR相似;所有疫苗耐受良好, solicited反应原性特征相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic is over but the highly immunized or naturally exposed global population still requires booster vaccinations against newly emerging SARS-CoV-2 variants. We assessed safety and immunogenicity of booster doses of COVID-19 vaccines based on three different platforms in a setting that mimics the current routine practice in Brazil. METHODS: In this phase 3 study from 14 February 2023 to 12 June 2023 we enrolled previously immunized adults to receive an additional booster dose of one of three vaccines. Immunogenicity against ancestor SARS-CoV-2 and Omicron BF.7, BQ.1.1.3, and XBB.1.5.6 sub-lineages was measured as ELISA IgG or virus neutralizing (VNT) antibodies and safety/reactogenicity assessed using diary cards. RESULTS: Volunteers with a history of full primary COVID-19 immunization striated to three cohorts according to their previous booster vaccination history-0 (n = 26), 1 (n = 140) or 2 (n = 606) booster vaccinations-were randomized 2:1:1 to receive either recombinant protein (SCB-2019, Clover), adenovirus-vector (ChAdOx1-S, AstraZeneca/Fiocruz), or mRNA (BNT162b2, Pfizer/Wyeth). Baseline antibody titers were higher in individuals who had received one or two boosters and titers against both ancestor and Omicron sub-lineages increased in all groups regardless of the number of previous booster doses or the vaccine used. Day 28 geometric mean titers (GMTs) and geometric mean-fold rises (GMFR) against all variants were higher after BNT162b than SCB-2019 or ChAdOx1-S, but BNT162b groups displayed more rapid antibody waning at Day 84. Within cohorts each vaccine elicited similar GMFR against the different SARS-CoV-2 strains. All vaccines were well tolerated with similar solicited reactogenicity profiles. CONCLUSIONS: Protein, adenovirus-vector or mRNA vaccine boosters were equally well tolerated and immunogenic against ancestor SARS-CoV-2 and Omicron sub-lineages in fully primed adults with 0-2 prior boosters. BNT162b induced the highest immune responses but also the most rapid waning of antibodies 3 months after vaccination. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT05812586.
引用
- Ann Costa Clemens S, Weckx L, Milan EP, et al. Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice. Vaccine. 2024. PMID: 38762360. doi:10.1016/j.vaccine.2024.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。